H1N1 Vaccine Global Market Report 2026

H1N1 vaccines are administered to individuals aged six months and older to protect against influenza caused by the H1N1 2009 virus. They work by introducing a small dose of the virus into the body, stimulating the immune system to build protection against infection.

The main types of H1N1 vaccines include inactivated vaccines and live attenuated vaccines. The inactivated vaccine segment comprises H1N1 vaccine products designed to prevent disease caused by the influenza H1N1 virus. Inactivated vaccines are synthetic formulations that provide protective immunity and contain hemagglutinin (HA) antigens derived from four inactivated influenza viruses: two influenza type A strains and two influenza type B strains. These vaccines are administered via intradermal, intramuscular, or subcutaneous routes and are used by hospitals, clinics, research and diagnostic laboratories, and other healthcare facilities.

Tariffs have created mixed effects on the h1n1 vaccine market by increasing costs for imported raw materials, bioreactors, syringes, and cold-chain equipment used in vaccine manufacturing and distribution. These cost pressures particularly affect inactivated and live attenuated vaccine segments and regions reliant on imports, such as parts of asia-pacific, africa, and latin america. Higher tariffs can delay vaccine availability and raise procurement costs for public immunization programs. However, tariffs have also encouraged local vaccine manufacturing, technology transfer, and regional self-sufficiency, strengthening domestic production capabilities in select markets.

The h1n1 vaccine market research report is one of a series of new reports from The Business Research Company that provides h1n1 vaccine market statistics, including h1n1 vaccine industry global market size, regional shares, competitors with a h1n1 vaccine market share, detailed h1n1 vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the h1n1 vaccine industry. This h1n1 vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The h1n1 vaccine market size has grown strongly in recent years. It will grow from $3.52 billion in 2025 to $3.78 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to past h1n1 pandemic outbreaks, government-led mass immunization campaigns, rising global influenza incidence, public health funding for vaccines, established cold chain infrastructure.

The h1n1 vaccine market size is expected to see strong growth in the next few years. It will grow to $5.05 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to increasing pandemic preparedness initiatives, rising elderly population vulnerability, expansion of national immunization schedules, growth in healthcare access in emerging economies, ongoing influenza virus mutation risks. Major trends in the forecast period include expansion of seasonal and pandemic influenza immunization programs, rising use of intranasal vaccines for improved patient compliance, increasing government stockpiling of h1n1 vaccines, growth in pediatric and geriatric vaccination coverage, enhanced focus on rapid vaccine distribution during outbreaks.

The increasing prevalence of chronic diseases is expected to drive the growth of the H1N1 vaccine market in the coming years. Chronic diseases are long-term health conditions that typically persist for three months or more and require ongoing medical care, including illnesses such as diabetes, heart disease, and arthritis. The rise in chronic diseases is largely linked to unhealthy lifestyle choices, such as poor diet, physical inactivity, and tobacco or alcohol use, which contribute to obesity, high blood pressure, and other long-term health risks. H1N1 vaccines play a vital role in protecting individuals with chronic conditions by reducing the risk of severe flu-related complications, preventing disease exacerbations, and lowering rates of hospitalization and mortality among vulnerable populations. For example, in June 2024, the National Health Service, a UK-based government agency, reported that 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023-an 18% increase from 3,065,825 cases in 2022. Therefore, the growing prevalence of chronic diseases is fueling the demand for H1N1 vaccines.

Leading companies in the H1N1 vaccine market are introducing innovative products, such as needle-free nasal vaccines, to maintain a competitive edge. Needle-free nasal vaccines eliminate the need for traditional needles or syringes, offering a non-invasive, painless method of administration through the nasal route. For example, in October 2023, Serum Institute, an India-based vaccine manufacturer, in collaboration with Mylab, an India-based diagnostic company, launched Nasovac S4-a needle-free nasal influenza vaccine designed to actively immunize against H1N1 and H3N2 viruses. The vaccine uses strains from both influenza Type A and Type B viruses to stimulate antibody production and can be administered to individuals aged 2 years and older to enhance immune protection against influenza.

In July 2023, Sinovac Biotech Ltd., a China-based biopharmaceutical company, partnered with Bio Farma to address human diseases. The collaboration targets both Indonesia's domestic vaccine market and international markets. The strategic partnership also enables Sinovac to introduce future products, including varicella, influenza, and pneumococcal polysaccharide vaccines, to meet regional healthcare needs and strengthen local and national public health initiatives. Bio Farma, based in Indonesia, is a state-owned biopharmaceutical company active in various segments of the vaccine market.

Major companies operating in the h1n1 vaccine market are Sanofi SA, GlaxoSmithKline PLC, CSL Limited, AstraZeneca Inc., Zydus Lifesciences Limited, Merck and Co.Inc., Novavax Inc., Panacea Biotec Ltd., Sinovac Biotech Ltd., Green Cross Corp., Pfizer Inc., Seqirus Ltd., Cipla Inc., Protein Sciences Corporation, Hualan Biological Engineering Inc., Changsheng Bio-Technology Co. Ltd., Bharat Biotech International Limited, Serum Institute of India Pvt. Ltd., Bio Farma Group, PT Kalbe Farma Tbk, Moderna Inc., CureVac NV, BioNTech SE, Inovio Pharmaceuticals Inc., Vaxart Inc., Altimmune Inc., Dynavax Technologies Corporation, VBI Vaccines Inc., GeoVax Labs Inc.

North America was the largest region in the H1N1 vaccine market in 2025. The regions covered in the h1n1 vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the h1n1 vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H1N1 vaccines market consists of sales of TIV (flu shot (injection) and LAIV (nasal spray (mist) of live attenuated influenza vaccine). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

H1N1 Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses h1n1 vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for h1n1 vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The h1n1 vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product Type: Inactivated Vaccine; Live Attenuated Vaccine
• 2) By Route Of Administration: Intradermal Vaccination; Intramuscular Vaccination; Subcutaneous Vaccination
• 3) By End Users: Hospitals; Clinics; Research And Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Inactivated Vaccine: Injectable Inactivated Vaccine; Intranasal Inactivated Vaccine
• 2) By Live Attenuated Vaccine: Injectable Live Attenuated Vaccine; Intranasal Live Attenuated Vaccine
• Companies Mentioned: Sanofi SA; GlaxoSmithKline PLC; CSL Limited; AstraZeneca Inc.; Zydus Lifesciences Limited; Merck and Co.Inc.; Novavax Inc.; Panacea Biotec Ltd.; Sinovac Biotech Ltd.; Green Cross Corp.; Pfizer Inc.; Seqirus Ltd.; Cipla Inc.; Protein Sciences Corporation; Hualan Biological Engineering Inc.; Changsheng Bio-Technology Co. Ltd.; Bharat Biotech International Limited; Serum Institute of India Pvt. Ltd.; Bio Farma Group; PT Kalbe Farma Tbk; Moderna Inc.; CureVac NV; BioNTech SE; Inovio Pharmaceuticals Inc.; Vaxart Inc.; Altimmune Inc.; Dynavax Technologies Corporation; VBI Vaccines Inc.; GeoVax Labs Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.